Tenaya Therapeutics does not pay a cash dividend to its common stockholders, resulting in a dividend yield of zero percent. As a clinical-stage biopharmaceutical enterprise focused on research and development, the company preserves all available capital to fund ongoing scientific trials, laboratory operations, and gene therapy platform scaling.